Alto Neuroscience announced the completion of enrollment in its Phase 2b study of ALTO-100 in adults with major depressive disorder, or MDD. Topline results from this study are expected to be reported in October.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO: